aidsmap news story
AIDS 2026 featured few new scientific breakthroughs in terms of vaccines or cures for HIV. But as well as featuring two more cases of cure following stem-cell transplants, a range of studies were presented that shed new light on how we might achieve a less drastic and more accessible form of cure, or at least enable people not to have to take regular antiretroviral therapy (ART).
In one of the most well-received plenary talks at the conference, Professor Michel Nussenzweig, head of the Laboratory of Molecular Immunology at the Rockefeller University in New York, reviewed several studies that used broadly neutralising antibodies (bnAbs) as potential cure agents. They have enabled a significant proportion of participants to maintain undetectable or low viral loads for prolonged periods without taking ART – in other words, to be in remission.
The proportion of people in these studies experiencing prolonged remission off ART is higher than what had been seen before. Nussenzweig said that the most interesting scientific findings have come from delving into what, exactly, was happening within the immune responses of people who achieved remission, and how they differed from those in people who ‘rebounded’ as soon as ART was withdrawn.
These studies have turned upside down several assumptions about how we might achieve a generalisable cure for HIV.
Read the full news story here.
View all aidsmap reports from AIDS 2026
Explore further: Full coverage of AIDS 2026
Source : aidsmap
Related HIV and Co-Infections News
-
[AIDS 2026] aidsmap: Scientists are developing on-target HIV vaccines to avoid unhelpful immune responses
-
[AIDS 2026] aidsmap: A new class of drugs could sharpen the body’s immune response to HIV
-
[AIDS 2026] aidsmap: Could leronlimab, a CCR5 blocker, be used to facilitate stem-cell transplant cures of HIV?
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.